Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials

PURPOSE: An oxymetazoline 0.1% ophthalmic solution was recently approved for treatment of acquired blepharoptosis in adults. This study’s objective was to evaluate the safety profile of oxymetazoline 0.1% when administered once daily for 14–84 days. PATIENTS AND METHODS: Pooled analysis examined saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirta, David L, Korenfeld, Michael S, Foster, Shane, Smyth-Medina, Robert, Bacharach, Jason, Kannarr, Shane R, Jaros, Mark J, Slonim, Charles B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517985/
https://www.ncbi.nlm.nih.gov/pubmed/34675472
http://dx.doi.org/10.2147/OPTH.S322326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517985/
https://www.ncbi.nlm.nih.gov/pubmed/34675472
http://dx.doi.org/10.2147/OPTH.S322326

Ejemplares similares